-
2 楼 发表于2011-03-06 11:13:00举报|引用
-
返回顶部 | 快捷回复
Angiotensin II Type I Receptor Blocker Is Limited in Protection Against Severe Podocyte Injury-Induced FSGS.
Hai-Chun
Yang, Shu-Wei Wang, Ira Pastan, Taiji Matsusaka, Iekuni Ichikawa, Agnes
B Fogo. Vanderbilt University Medical Center, Nashville, TN; National
Cancer Instiute, National Instiute of Health, Bethesda, MD; Tokai
University Medical School, Isehara, Kanagawa, Japan
Background:
In 5/6 Nx models in both rats and mice, we found high dose angiotensin
II type I receptor blocker (ARB) prevented glomerulosclerosis
progression and even could induce regression. Nep25 mice, which express
the human CD25 receptor on podocytes, can dose-dependently develop
progressive glomerulosclerosis when immunotoxin (LMB2) is administered
and binds this receptor. Previously we have shown that renal collagen I
expression was parallel to luciferin imaging in double transgenic
Nep25/collagen I-luciferase mice with glomerulosclerosis induced by this
toxin. In this study, we aimed to examine if ARB could protect in this
model of severe primary podocyte injury-associated FSGS.
Design:
Collagen I-luciferase/Nep 25 mice were exposed to a mean dose of LMB2
toxin (12.5 ng/g BW, i.p.). Mice were biopsied at week 2, randomly
assigned to the ARB losartan (200mg/L) or not treated (control group),
then sacrificed at week 6. Podocyte number, urine total
protein/creatinine ratio, glomerulosclerosis index (SI, 0-4 scale) and
collagen I associated luciferase activity were measured.
Results: LMB2 reduced podocyte number about 40% assessed by WT-1 staining (normal 7.50±0.50 vs.
LMB2 4.64±0.11 /glomerulus). The control group showed edema and
persistent proteinuria (week 2 66.06±14.51, week 4 72.52±11.40, week 6
87.33±29.57). Progressive glomerulosclerosis (SI, week 2 1.26±0.11 vs.
week 6 1.81±0.04, p<0.05) and increased collagen I activity also
developed (luciferase imaging score, week 2 0.84±0.13, week 4 1.66±0.09,
week 6 1.79±0.001 ×e6, p<0.05 overtime) in control
toxin-treated mice. Losartan stabilized collagen I activity (luciferase
imaging score, week 2 0.96±0.18, week 4 0.78±0.10, week 6 1.06±0.13 ×e6).
However, ARB did not decrease proteinuria (week 2 96.18±16.53, week 4
94.10±11.96, week 6 73.76±7.92, pNS) and did not prevent
glomerulosclerosis progression (SI, week 2 1.48±0.15 vs. week 6 2.09±0.19, p<0.05).
Conclusions:
Our data indicate that severe podocyte loss causes progressive
glomerulosclerosis, and ARB alone cannot prevent glomerulosclerosis
progression in this setting. This may be related to continuing podocyte
loss cycle which accelerates the progression process.
Angiotensin II Type I Receptor Blocker Is Limited in Protection Against Severe Podocyte Injury-Induced FSGS.
Hai-Chun
Yang, Shu-Wei Wang, Ira Pastan, Taiji Matsusaka, Iekuni Ichikawa, Agnes
B Fogo. Vanderbilt University Medical Center, Nashville, TN; National
Cancer Instiute, National Instiute of Health, Bethesda, MD; Tokai
University Medical School, Isehara, Kanagawa, Japan
Background:
In 5/6 Nx models in both rats and mice, we found high dose angiotensin
II type I receptor blocker (ARB) prevented glomerulosclerosis
progression and even could induce regression. Nep25 mice, which express
the human CD25 receptor on podocytes, can dose-dependently develop
progressive glomerulosclerosis when immunotoxin (LMB2) is administered
and binds this receptor. Previously we have shown that renal collagen I
expression was parallel to luciferin imaging in double transgenic
Nep25/collagen I-luciferase mice with glomerulosclerosis induced by this
toxin. In this study, we aimed to examine if ARB could protect in this
model of severe primary podocyte injury-associated FSGS.
Design:
Collagen I-luciferase/Nep 25 mice were exposed to a mean dose of LMB2
toxin (12.5 ng/g BW, i.p.). Mice were biopsied at week 2, randomly
assigned to the ARB losartan (200mg/L) or not treated (control group),
then sacrificed at week 6. Podocyte number, urine total
protein/creatinine ratio, glomerulosclerosis index (SI, 0-4 scale) and
collagen I associated luciferase activity were measured.
Results: LMB2 reduced podocyte number about 40% assessed by WT-1 staining (normal 7.50±0.50 vs.
LMB2 4.64±0.11 /glomerulus). The control group showed edema and
persistent proteinuria (week 2 66.06±14.51, week 4 72.52±11.40, week 6
87.33±29.57). Progressive glomerulosclerosis (SI, week 2 1.26±0.11 vs.
week 6 1.81±0.04, p<0.05) and increased collagen I activity also
developed (luciferase imaging score, week 2 0.84±0.13, week 4 1.66±0.09,
week 6 1.79±0.001 ×e6, p<0.05 overtime) in control
toxin-treated mice. Losartan stabilized collagen I activity (luciferase
imaging score, week 2 0.96±0.18, week 4 0.78±0.10, week 6 1.06±0.13 ×e6).
However, ARB did not decrease proteinuria (week 2 96.18±16.53, week 4
94.10±11.96, week 6 73.76±7.92, pNS) and did not prevent
glomerulosclerosis progression (SI, week 2 1.48±0.15 vs. week 6 2.09±0.19, p<0.05).
Conclusions:
Our data indicate that severe podocyte loss causes progressive
glomerulosclerosis, and ARB alone cannot prevent glomerulosclerosis
progression in this setting. This may be related to continuing podocyte
loss cycle which accelerates the progression process.
- 0